AZTherapies – Harnessing the Power of Neuro-Immunology

Time 2020-11-09 01:04:41

Web Name: AZTherapies – Harnessing the Power of Neuro-Immunology

WebSite: http://aztherapies.com

ID:109531

Keywords:

the,Harnessing,AZTherapies,

Description:

Changing Neurodegenerative Disease Progression HARNESSING THE POWER OF NEURO-IMMUNOLOGY Developing novel therapies that aim to fundamentally change neurodegenerative disease progression by targeting neuroinflammation AZTherapies Home 01 PIONEERING SCIENCE AZTherapies’ scientific approach recognizes neuroinflammation as a root cause of serious neurodegenerative disease. By shifting the brain’s own immune cells, the microglia, from an aggressive, pro-inflammatory state to a neuroprotective state, we aim to treat a broad array of serious diseases. A GROWING PIPELINE Our lead program is built on a multi-modal approach that seeks to stop or slow the progression of early Alzheimer’s disease. We are also advancing candidates for the treatment of post-ischemic stroke cognitive impairment, ALS, and Parkinson’s disease. LEADERS IN INNOVATION We have assembled unique, results-driven and highly engaged leadership and advisory teams to advance our pipeline, improve the lives of patients with serious neurodegenerative diseases, and build a company of exceptional value. October 1, 2020 AZTherapies Announces Leadership Transition, Appointing Marc de Garidel Chief Executive Officer and Member of the Board of Directors Company founder David R. Elmaleh, Ph.D., remains Executive Chairman of the Board and Chief Scientific Officer September 29, 2020 AZTherapies Announces Closing of $33.6 Million Series C-1 Financing Building Upon Recent $37.5 Million Series C Financing Proceeds will help AZTherapies expand regulatory and pre-commercial activities related to Phase 3 candidate for early Alzheimer’s disease and advance other neuroinflammation-targeted programs September 9, 2020 AZTherapies Doses First Patient in Phase 2a Study of ALZT-OP1a in Amyotrophic Lateral Sclerosis (ALS) Randomized, open-label, multi-center, dose optimization study expected to evaluate 80 patients with mild- to moderate-stage ALS

TAGS:the Harnessing AZTherapies 

<<< Thank you for your visit >>>

AZTherapies is a Boston-based life science company targeting neuroinflammation and developing novel therapies to treat neurodegenerative diseases.

Hot Websites